Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

Abstract: The present invention relates to a combination of sensors, a system and a method for monitoring incontinence and physiological parameters. The system includes a plurality of electrodes on an absorbent article including an absorbent core to be worn by a wearer being monitored, a device for electrical connection with the electrodes and for monitoring one or more electrical properties of the electrodes indicative of the occurrence of an incontinence event, an oxygen saturation sensor for monitoring the oxygen saturation of the blood of the wearer, and wherein the operation of the oxygen saturation sensor is controlled according to the body position of the wearer.

Abstract: Systems and methods for identifying patterns in blockchain activities based on multi-modal data using artificial intelligence models that compensate for training data featuring a high proportion of missing data points. For example, the system may receive blockchain activity record data for a plurality of blockchain activities involving a plurality of blockchain accounts. The system may input the data into an artificial intelligence model, wherein the artificial intelligence model is trained to identify serial relationships of related blockchain activities corresponding to inputted target blockchain activities based on proportions of digital assets at subsets of blockchain accounts of the plurality of blockchain accounts. The system may receive an output from the artificial intelligence model. The system may generate for display, in a user interface, a visualization of the target blockchain activity based on the output.

Abstract: The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Abstract: The present disclosure is directed to dual specific antibodies, which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: Disclosed herein are systems and methods for tracking and managing location information for automobile assets. By affixing passive transmitter tags with unique identification information to automobile assets, location information may be associated with designated areas and/or location information by scanning the passive transmitter tags at various scan points. The location and automobile asset information may be stored, read, and updated in a centralized cloud database platform, accessible at varying levels to suppliers, manufacturers, shippers, and others.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.

Abstract: Provided herein are chimeric scavenger receptor where the endogenous binding region is replaced with an antigen-specific binding region to redirect the specificity of the receptor. Also provided are immune cells, such as, for example, monocytes, that are engineered to express the chimeric scavenger receptor. Also provided are methods of treating patients, such as, for example, Alzheimer's patients, by administering the engineered monocytes.

Abstract: Isolated or recombinant monoclonal antibodies that bind to 4-1BB are provided. In son cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Abstract: This invention relates to a high-performance, low-cost water capacitive deionization and hydrogen electrolyzer system that can operate from AC or DC power sources and manage and store power when coupled with renewable energy sources.

Abstract: Disclosed herein are systems and methods for tracking and managing location information for automobile assets. By affixing passive transmitter tags with unique identification information to automobile assets, location information may be associated with designated areas and/or location information by scanning the passive transmitter tags at various scan points. The location and automobile asset information may be stored, read, and updated in a centralized cloud database platform, accessible at varying levels to suppliers, manufacturers, shippers, and others.

Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Abstract: Disclosed herein are systems and methods for tracking and managing location information for automobile assets. By affixing passive transmitter tags with unique identification information to automobile assets, location information may be associated with designated areas and/or location information by scanning the passive transmitter tags at various scan points. The location and automobile asset information may be stored, read, and updated in a centralized cloud database platform, accessible at varying levels to suppliers, manufacturers, shippers, and others.